Quantcast

The National Mesothelioma Law Firm of Baron and Budd Reports on a New Drug that Could Improve the Health of Mesothelioma Patients

December 18, 2012

Mesothelioma Lawyers raising awareness of new drug that could help improve the health of mesothelioma patients.

Dallas, TX (PRWEB) December 17, 2012

The national mesothelioma law firm of Baron and Budd reports that a new experimental drug may help limit the negative side affects associated with mesothelioma treatment. Dr. Adrian Dobs, Professor of Medicine and Oncology and Vice Chair of Medicine at John Hopkins University headed the clinical trial for the drug, Enobosarm, and discovered that male and female cancer patients had significant improvement in muscle mass and power after taking the drug. The firm, dedicated to protecting the rights of mesothelioma patients, is always glad to support and raise awareness about advancements in mesothelioma treatment and care.

“This is another step forward in the medical battle against mesothelioma,” said John Langdoc, mesothelioma lawyer at Baron and Budd. “Patients and caregivers need to be aware of these newer developments and we are proud to assist in the awareness process.”

Currently, mesothelioma doctors typically use a multi-modal approach of surgery, radiation and chemotherapy treatment. The combination of treatments is quite aggressive, and can lead to adverse side affects such as nausea, vomiting, and weight loss. Researchers recently gave the experimental drug Enobosarm, to patients receiving these cancer treatments and reported a significant decrease in muscle loss.

In the Phase IIb clinical trial, Dr. Dobs led a randomized test with 159 subjects given either Enobosarm or a placebo for a total of 16 weeks. Enobosarm is a selective androgen receptor modulator (SARM), a non-steroidal drug that produces the anabolic effect in bone and muscle without causing the negative prostate effects in men or hair growth in women that is associated with steroidal treatment.

According to Dr. Dobs, Phase III of the trial will assess the effects of a 3mg/day dosage of Enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

The usage of a drug like Enobosarm could greatly aid in the health of mesothelioma patients when receiving radiation and chemotherapy treatments.

The national mesothelioma law firm of Baron and Budd has been dedicated to the development of mesothelioma research and treatment and is excited to report on the improvement in medications for mesothelioma patients. The firm is proud of its work with organizations like the National Comprehensive Cancer Network and Cure Media Group as well as several others, and it committed to relating any relevant information to the people affected by mesothelioma.

For more information about Enobosarm and the clinical trials at John Hopkins University Medical Center, read the more about the study in “Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting in a Phase IIb Enobosarm Trial,” published June 24, 2012.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10209590.htm


Source: prweb



comments powered by Disqus